
|Videos|January 30, 2023
Updates on Selinexor Triplet Combination Therapies from ASH 2022
Author(s)Joshua Richter, MD, Srdan Verstovsek, MD, PhD
Joshua Richter, MD, highlights key data from an update to a study investigating a selinexor triplet combination therapy.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
3
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
4
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
5










































